| Dr Beth A Berlin, OD | |
|
21 Torrey St, Brockton, MA 02301-4849 | |
| (719) 576-1850 | |
| Not Available |
| Full Name | Dr Beth A Berlin |
|---|---|
| Gender | Female |
| Speciality | Optometry |
| Experience | 19 Years |
| Location | 21 Torrey St, Brockton, Massachusetts |
| Accepts Medicare Assignments | May be. She may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1609055334 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 4652 (Massachusetts) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Bouquet Mulligan Demaio Eye Professionals P.c. | 7517918394 | 4 |
News Archive
NeurAxon, Inc., a development-stage pharmaceutical company that is designing and developing next-generation pain therapeutics targeting neuronal nitric oxide synthase (nNOS), today announced that it has closed a convertible debenture financing in which the convertible debentures are convertible under specified circumstances into existing class B preferred shares for a total of approximately $14 million.
A team of researchers conduct a large study exploring the persistence of COVID-19 symptoms in recovered patients.
Life Technologies Corporation today announced plans for the Applied Biosystems SOLiD™ PI System, a new highly accurate, flexible and easy-to-use genomic analysis platform that will bring next-generation sequencing within the grasp of all life science research laboratories worldwide. Early customer adoption of the SOLiD PI System is expected to begin in the second half of 2010.
A new technology suitable for practical clinical testing can detect KRAS gene mutations in lung and colorectal cancers and could thereby facilitate targeted therapies, according to a new report in The Journal of Molecular Diagnostics.
If all patients scheduled for knee replacement were directed to high-volume hospitals for the surgery, it could save the U.S. healthcare system between $2.5 and $4 billion annually by the year 2030, according to a study at Hospital for Special Surgery in New York City.
› Verified 5 days ago
| Provider Name | Bouquet Mulligan Demaio Eye Professionals P.c. |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1568493351 PECOS PAC ID: 7517918394 Enrollment ID: O20050209000581 |
News Archive
NeurAxon, Inc., a development-stage pharmaceutical company that is designing and developing next-generation pain therapeutics targeting neuronal nitric oxide synthase (nNOS), today announced that it has closed a convertible debenture financing in which the convertible debentures are convertible under specified circumstances into existing class B preferred shares for a total of approximately $14 million.
A team of researchers conduct a large study exploring the persistence of COVID-19 symptoms in recovered patients.
Life Technologies Corporation today announced plans for the Applied Biosystems SOLiD™ PI System, a new highly accurate, flexible and easy-to-use genomic analysis platform that will bring next-generation sequencing within the grasp of all life science research laboratories worldwide. Early customer adoption of the SOLiD PI System is expected to begin in the second half of 2010.
A new technology suitable for practical clinical testing can detect KRAS gene mutations in lung and colorectal cancers and could thereby facilitate targeted therapies, according to a new report in The Journal of Molecular Diagnostics.
If all patients scheduled for knee replacement were directed to high-volume hospitals for the surgery, it could save the U.S. healthcare system between $2.5 and $4 billion annually by the year 2030, according to a study at Hospital for Special Surgery in New York City.
› Verified 5 days ago
| Provider Name | Custom Eyes Rx Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1982732715 PECOS PAC ID: 9739126459 Enrollment ID: O20050414000413 |
News Archive
NeurAxon, Inc., a development-stage pharmaceutical company that is designing and developing next-generation pain therapeutics targeting neuronal nitric oxide synthase (nNOS), today announced that it has closed a convertible debenture financing in which the convertible debentures are convertible under specified circumstances into existing class B preferred shares for a total of approximately $14 million.
A team of researchers conduct a large study exploring the persistence of COVID-19 symptoms in recovered patients.
Life Technologies Corporation today announced plans for the Applied Biosystems SOLiD™ PI System, a new highly accurate, flexible and easy-to-use genomic analysis platform that will bring next-generation sequencing within the grasp of all life science research laboratories worldwide. Early customer adoption of the SOLiD PI System is expected to begin in the second half of 2010.
A new technology suitable for practical clinical testing can detect KRAS gene mutations in lung and colorectal cancers and could thereby facilitate targeted therapies, according to a new report in The Journal of Molecular Diagnostics.
If all patients scheduled for knee replacement were directed to high-volume hospitals for the surgery, it could save the U.S. healthcare system between $2.5 and $4 billion annually by the year 2030, according to a study at Hospital for Special Surgery in New York City.
› Verified 5 days ago
| Provider Name | Monroe Vision And Hearing Center Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1497821235 PECOS PAC ID: 6901844778 Enrollment ID: O20050421000863 |
News Archive
NeurAxon, Inc., a development-stage pharmaceutical company that is designing and developing next-generation pain therapeutics targeting neuronal nitric oxide synthase (nNOS), today announced that it has closed a convertible debenture financing in which the convertible debentures are convertible under specified circumstances into existing class B preferred shares for a total of approximately $14 million.
A team of researchers conduct a large study exploring the persistence of COVID-19 symptoms in recovered patients.
Life Technologies Corporation today announced plans for the Applied Biosystems SOLiD™ PI System, a new highly accurate, flexible and easy-to-use genomic analysis platform that will bring next-generation sequencing within the grasp of all life science research laboratories worldwide. Early customer adoption of the SOLiD PI System is expected to begin in the second half of 2010.
A new technology suitable for practical clinical testing can detect KRAS gene mutations in lung and colorectal cancers and could thereby facilitate targeted therapies, according to a new report in The Journal of Molecular Diagnostics.
If all patients scheduled for knee replacement were directed to high-volume hospitals for the surgery, it could save the U.S. healthcare system between $2.5 and $4 billion annually by the year 2030, according to a study at Hospital for Special Surgery in New York City.
› Verified 5 days ago
| Provider Name | Vision Innovation Centers Of Pa Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1962046458 PECOS PAC ID: 0840625349 Enrollment ID: O20200110000050 |
News Archive
NeurAxon, Inc., a development-stage pharmaceutical company that is designing and developing next-generation pain therapeutics targeting neuronal nitric oxide synthase (nNOS), today announced that it has closed a convertible debenture financing in which the convertible debentures are convertible under specified circumstances into existing class B preferred shares for a total of approximately $14 million.
A team of researchers conduct a large study exploring the persistence of COVID-19 symptoms in recovered patients.
Life Technologies Corporation today announced plans for the Applied Biosystems SOLiD™ PI System, a new highly accurate, flexible and easy-to-use genomic analysis platform that will bring next-generation sequencing within the grasp of all life science research laboratories worldwide. Early customer adoption of the SOLiD PI System is expected to begin in the second half of 2010.
A new technology suitable for practical clinical testing can detect KRAS gene mutations in lung and colorectal cancers and could thereby facilitate targeted therapies, according to a new report in The Journal of Molecular Diagnostics.
If all patients scheduled for knee replacement were directed to high-volume hospitals for the surgery, it could save the U.S. healthcare system between $2.5 and $4 billion annually by the year 2030, according to a study at Hospital for Special Surgery in New York City.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Beth A Berlin, OD 323 Normandy Dr, Norwood, MA 02062-1416 Ph: (781) 769-2158 | Dr Beth A Berlin, OD 21 Torrey St, Brockton, MA 02301-4849 Ph: (719) 576-1850 |
News Archive
NeurAxon, Inc., a development-stage pharmaceutical company that is designing and developing next-generation pain therapeutics targeting neuronal nitric oxide synthase (nNOS), today announced that it has closed a convertible debenture financing in which the convertible debentures are convertible under specified circumstances into existing class B preferred shares for a total of approximately $14 million.
A team of researchers conduct a large study exploring the persistence of COVID-19 symptoms in recovered patients.
Life Technologies Corporation today announced plans for the Applied Biosystems SOLiD™ PI System, a new highly accurate, flexible and easy-to-use genomic analysis platform that will bring next-generation sequencing within the grasp of all life science research laboratories worldwide. Early customer adoption of the SOLiD PI System is expected to begin in the second half of 2010.
A new technology suitable for practical clinical testing can detect KRAS gene mutations in lung and colorectal cancers and could thereby facilitate targeted therapies, according to a new report in The Journal of Molecular Diagnostics.
If all patients scheduled for knee replacement were directed to high-volume hospitals for the surgery, it could save the U.S. healthcare system between $2.5 and $4 billion annually by the year 2030, according to a study at Hospital for Special Surgery in New York City.
› Verified 5 days ago
Lynn Brandes, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 21 Torrey St, Brockton, MA 02301 Phone: 508-587-8344 | |
Edna Chiu, Optometrist Medicare: Accepting Medicare Assignments Practice Location: 21 Torrey Street, Brockton, MA 02301 Phone: 508-717-0425 | |
Dr. Barry M Fisch, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 940 Belmont St, Brockton, MA 02301 Phone: 774-826-1106 | |
Mass Optometric Associates, P.c. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 726 1/2 Belmont St, Taymor Shoe Plaza, Brockton, MA 02301 Phone: 508-587-9700 Fax: 508-587-0646 | |
Dr. Richard M Lubas, O.D. Optometrist Medicare: May Accept Medicare Assignments Practice Location: 700 Oak St, Brockton, MA 02301 Phone: 508-584-8886 Fax: 508-584-8500 | |
Dr. Megan Lynn Cope, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 940 Belmont St, Brockton, MA 02301 Phone: 774-826-1106 | |
Dr. Bryanna Morgan Caron, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 940 Belmont St, Brockton, MA 02301 Phone: 508-583-4500 |